CJC-1295 and Ipamorelin Stack: How the Combination Works

How the CJC-1295 and Ipamorelin stack is proposed to work, the difference between CJC-1295 with and without DAC, timing concepts, side effects and monitoring.

Signal IQ Editorial5 min read · Updated Nov 8, 2026
CJC-1295 and Ipamorelin Stack: How the Combination Works
In this article
  1. How the two compounds work
  2. CJC-1295 with DAC versus without DAC
  3. Why fasting comes up
  4. Dosing and cycling
  5. What users and researchers report
  6. Side effects and how they relate to GH
  7. Combining with other compounds
  8. Frequently asked questions

The CJC-1295 and ipamorelin stack combines two growth hormone secretagogues that act on different receptors in the pituitary gland. CJC-1295 mimics growth hormone releasing hormone (GHRH), and ipamorelin mimics ghrelin’s action on the growth hormone secretagogue receptor. Researchers pair them because the two signals together are expected to produce a larger growth hormone pulse than either alone. Both are research compounds and are not approved for human use.

Key takeaways
  • CJC-1295 acts on the GHRH receptor; ipamorelin acts on the ghrelin receptor, so the stack engages two release pathways.
  • CJC-1295 exists with and without a DAC modification, and the two versions differ greatly in how long they stay in circulation.
  • Growth hormone release is blunted by high insulin, which is why research protocols discuss fasting windows.
  • Published human data on this specific combination are limited, and more growth hormone signaling is not automatically better.

How the two compounds work

CJC-1295 is a synthetic analog of GHRH. It binds GHRH receptors on the pituitary and signals the gland to make and release growth hormone (GH). In simple terms, it is the “release more” signal.

Ipamorelin is a growth hormone releasing peptide that works through ghrelin receptors. It is regarded as relatively selective: in the studies cited by the source, it stimulates GH without meaningfully raising cortisol or prolactin, which distinguishes it from some older compounds in its class.

The rationale for stacking is that two separate inputs converge on the same output. That synergy is a reasonable expectation from the pharmacology, but human trials of the combination itself remain limited.

CJC-1295 with DAC versus without DAC

“DAC” stands for drug affinity complex, a chemical modification that lets the peptide bind albumin in the blood and so persist far longer. This single difference changes how the stack behaves.

With DACWithout DAC (Mod GRF 1-29)
Approximate half-lifeSeveral days (about a week)Roughly 30 minutes
GH patternSustained, elevated baselineShort, pulsatile peaks
Pairing with ipamorelinIpamorelin is given separately from the long-acting CJCBoth are given together in the same session
Main appealFewer injectionsCloser to natural GH pulsatility

Natural GH release is pulsatile, with the largest pulses during deep sleep. The no-DAC version is generally described as the closer imitation of that rhythm, while the DAC version trades pulse shape for convenience. Neither has been shown in a trial to be superior for any particular outcome.

Why fasting comes up

Elevated insulin and high blood glucose suppress GH release. Because of this, research and community protocols describe giving secretagogues in a fasted window, with a gap after the last meal, and they commonly mention pre-sleep timing because it overlaps the body’s natural GH peak. This is a pharmacological reasoning point, not a proven schedule.

Dosing and cycling

Dose and schedule figures for this combination vary enormously across sources, and no controlled human trial sets a standard. Signal IQ publishes the research-protocol ranges it considers consistent with the literature on the CJC-1295 + Ipamorelin compound page, and this article defers to those rather than repeating other numbers.

Note: CJC-1295 and ipamorelin are research-use-only and not FDA-approved for human use. Anything described here is educational. Decisions about use should involve a qualified clinician, who can also assess whether growth hormone axis changes are appropriate for you.

In general terms, protocols describe running the stack in defined blocks followed by a break, because continuous stimulation is thought to reduce pituitary responsiveness over time. The same compound page covers cycle concepts, and the broader topic is covered in peptide cycling.

What users and researchers report

The source describes a gradual course: effects are slow and cumulative rather than fast. Reported experiences include changes in sleep quality early on and body-composition or recovery changes later. These are anecdotal, depend heavily on training, nutrition and sleep, and cannot be separated from placebo effects without controlled data.

Side effects and how they relate to GH

  • Fluid retention and puffiness: a typical GH effect, usually early on.
  • Tingling or numbness in the hands: associated with higher GH exposure and a signal to reassess.
  • Increased hunger and fatigue: reported, particularly early.
  • Injection-site reactions: rotating sites is standard hygiene; see peptide injection sites.
  • Glucose effects: GH can reduce insulin sensitivity, so fasting glucose is a sensible marker.

More general safety points are in peptide side effects. IGF-1 is the most commonly cited marker for the GH axis, and the Bloodwork Panel Planner can help organize baseline and follow-up labs.

Combining with other compounds

Online discussions commonly place this stack alongside other peptides. Two points are mechanistic rather than anecdotal: combining a long-acting GHRH analog with another GHRH analog such as tesamorelin duplicates the same receptor target, and compounds that act on unrelated pathways, such as the BPC-157 and TB-500 stack or MOTS-c, have not been tested in combination with it in humans. Interactions are therefore unknown.

For handling basics see can you mix peptides in the same syringe, how to reconstitute peptides, and how to read a peptide CoA. Browse the Signal Library or ask Pulse for related compounds.

Frequently asked questions

What is the CJC-1295 and ipamorelin stack?

A combination of a GHRH analog and a ghrelin-receptor agonist, each stimulating growth hormone release through a different pituitary pathway.

What is the difference between CJC-1295 with and without DAC?

DAC lets the peptide bind albumin and stay in circulation for days, while the version without DAC clears in about half an hour and produces short pulses.

Can CJC-1295 and ipamorelin be mixed in one syringe?

Research descriptions treat the short-acting no-DAC version and ipamorelin as given together in a session, while the long-acting DAC version is separate. See the syringe guide linked above for general principles.

Why is fasting emphasized?

High insulin and glucose blunt GH release, so a fasted window is expected to produce a larger response from the same stimulus.

Is this stack FDA-approved?

No. Both compounds are research materials without approval for human use.

Is it safe alongside GLP-1 drugs?

No trial data address this. The two classes act through different systems, but the combination has not been studied, so it is a question for a clinician.

Go deeper on Signal IQ

Dosing & protocolCJC-1295 + IpamorelinResearch profileCJC-1295 / IpamorelinDosing & protocolIpamorelinResearch profileIpamorelin

Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.

Ask Pulse

Educational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.

Keep reading